Fig. 5: Longitudinal analyses of peripheral blood immune cell populations. | Nature Communications

Fig. 5: Longitudinal analyses of peripheral blood immune cell populations.

From: Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial

Fig. 5

Cellular subsets from peripheral blood samples were identified via CyTOF and quantitated at baseline, after Cycle 1, after completion of neoadjuvant treatment (Cycle 3), and after operation (Cycle 4). A Relative composition of immune cells at each timepoint in individual patients, faceted by treatment cohort and response status. B Frequencies of select lymphocyte subtypes as a percentage of total PBMCs, grouped by pathologic response status (favorable: pCR or near-pCR, ≤10% viable tumor cells; poor: pPR or pNR, >10% viable tumor cells). An asterisk (*) denotes p < 0.05 (linear regression t-test, two sided adjusting treatmentarms). Jitters on the plot represent subjects. The lower and upper whiskers represent the range of data points within 1.5 times the interquartile range below or above the first and third quartiles respectively, while the box itself illustrates the middle 50% of the data, bounded by the first and third quartiles, with a median line indicating the data’s median value. C Change from baseline intensity of PD-L1 expression on T cells in individual BRAFm and BRAFwt patients. Bold lines denote mean values for each cohort.

Back to article page